Real world data on the use of cabozantinib plus immunotherapy in the second line
A recent study looked at the use of a combination [...]
METEOR study: Cabozantinib compared to everolimus in advanced kidney cancer
Cabozantinib is a tyrosine kinase inhibitor that is used [...]
FDA approves belzutifan for advanced kidney cancer
The Food and Drug Administration (FDA) in the United States [...]
ESMO 2023: Belzutifan for the treatment of advanced kidney cancer
Treatments for people with metastatic kidney cancer have changed over [...]
Belzutifan plus cabozantinib combination shows promising results in kidney cancer
Kidney cancers often have mutations in a gene called the [...]
ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
EIKCS 2022: Debate about later-line treatments
At the 2022 European International Kidney Cancer Symposium (EIKCS) in [...]
Sunitinib as a second-line treatment for advanced kidney cancer after combination immunotherapy
The results from a recent phase 2 trial looked at [...]
Immunotherapy after progression of metastatic kidney cancer
Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) are [...]
EIKCS 2021: Second-line and later treatments for metastatic kidney cancer
The increase in the number of first-line treatments for metastatic [...]
